The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018

被引：1

作者：

Ascierto, Paolo A. ^{[1
]}

Bruzzi, Paolo ^{[2
]}

Eggermont, Alexander ^{[4
]}

Hamid, Omid ^{[5
]}

Tawbi, Hussein A. ^{[7
]}

van Akkooi, Alexander ^{[9
]}

Testori, Alessandro ^{[8
]}

Caraco, Corrado ^{[3
]}

Puzanov, Igor ^{[6
]}

Perrone, Francesco ^{[10
]}

机构：

[1] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Melanoma Canc Immunotherapy & Innovat Therap, Via Mariano Semmola, I-80131 Naples, Italy

[2] Univ Hosp San Martino, Clin Epidemiol Unit, Genoa, Italy

[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Melanoma Soft Tissue Muscle Skeletal & Head, Naples, Italy

[4] Inst Gustave Roussy Villejuif, Paris Sud, Paris, France

[5] Angeles Clin & Res Inst, Clin Res & Immunotherapy, Los Angeles, CA USA

[6] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY USA

[7] UT MD Anderson Canc Ctr, Invest Canc Therapeut, Melanoma Med Oncol, Melanoma Clin Res & Early Drug Dev, Houston, TX USA

[8] EORTC Melanoma Grp, Surg Grp, Brussels, Belgium

[9] Netherlands Canc Inst Antoni van Leeuwenhoek Hosp, Dept Surg Oncol, Amsterdam, Netherlands

[10] Ist Nazl Tumori IRCCS Fdn G Pascale, Clin Trials Unit, Naples, Italy

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2019年 / 17卷

关键词：

Melanoma; Immunotherapy; Anti-PD-1; Anti-CTLA-4; Targeted therapy; BRAF inhibitor; MEK inhibitor; Adjuvant; Neoadjuvant; METASTATIC MELANOMA; STAGE-III; IPILIMUMAB; NIVOLUMAB; SURVIVAL; MULTICENTER; PROGRESSION; THERAPIES;

D O I：

10.1186/s12967-019-1892-5

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

引用

页数：11

共 45 条

[41] 4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece
Fortis, Sotirios P.
Kotsakis, Athanasios
Le Tourneau, Christophe
Tsitsilonis, Ourania E.
Georgoulias, Vassilis
Baxevanis, Constantin N.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (08) : 1391 - 1400
[42] CLINICAL-VALUE OF LYMPH-DRAINAGE SCINTIGRAPHY IN MALIGNANT-MELANOMA - 1ST EVALUATION OF 5 YEARS EXPERIENCE
BUCHALI, K
BLESIN, HJ
WINTER, H
SCHURER, M
NUC COMPACT-EUROPEAN-AMERICAN COMMUNICATIONS IN NUCLEAR MEDICINE, 1990, 21 (04): : 122 - 123
[43] Over 10 years relative median survival in MM patients ≤ 65 years with VGPR or better on 1st line treatment. Population-based data on patients diagnosed 2008-2018 from the Swedish Myeloma Registry
Blimark, Cecilie Hveding
Genell, Anna
Lund, Johan
Nahi, Hareth
Carlson, Kristina
Forsberg, Karin
Juliusson, Gunnar
Lauri, Birgitta
Linder, Olle
Danielsson, Signe
Svensson, Ronald
Vesskovski, Ljupco
Knut-Bojanowska, Dorota
Turesson, Ingemar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E209 - E209
[44] Study KBP-2010-CPHG: Inclusion of new cases of primary lung cancer diagnosed in general hospital pneumology departments between 1st January and 31 December 2010
Grivaux, M.
Locher, C.
Bombaron, P.
Collon, T.
Coetmeur, D.
Dayen, C.
Debieuvre, D.
Goupil, F.
Le Treut, J.
Martin, F.
Molinier, O.
Asselain, B.
Zureik, M.
Blanchon, F.
REVUE DE PNEUMOLOGIE CLINIQUE, 2010, 66 (06) : 375 - 382
[45] The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) - a real- life data report 2013-2018
Mesti, Tanja
Rebersek, Martina
Ocvirk, Janja
RADIOLOGY AND ONCOLOGY, 2023, 57 (01) : 103 - 110

← 1 2 3 4 5 →